Home
About
Overview
Sharing Data
ORCID
Help
History (15)
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Paramecium
Receptors, Transforming Growth Factor beta
Immunogenetics
Humulus
See All 15 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
vCard
Download vCard